- Previous Close
39.65 - Open
40.00 - Bid --
- Ask --
- Day's Range
39.95 - 40.40 - 52 Week Range
37.75 - 52.60 - Volume
21,251 - Avg. Volume
22,134 - Market Cap (intraday)
2.228B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
16.30 - EPS (TTM)
2.46 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield 2.04 (5.15%)
- Ex-Dividend Date Mar 25, 2024
- 1y Target Est
62.00
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
www.bbbiotech.ch/en/bb-biotech/Recent News: BBZA.DE
View MorePerformance Overview: BBZA.DE
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBZA.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBZA.DE
View MoreValuation Measures
Market Cap
2.19B
Enterprise Value
--
Trailing P/E
16.10
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.30
Price/Book (mrq)
0.91
Enterprise Value/Revenue
17.49
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
281.64%
Return on Assets (ttm)
0.31%
Return on Equity (ttm)
5.64%
Revenue (ttm)
44.51M
Net Income Avi to Common (ttm)
125.36M
Diluted EPS (ttm)
2.46
Balance Sheet and Cash Flow
Total Cash (mrq)
2.51B
Total Debt/Equity (mrq)
12.31%
Levered Free Cash Flow (ttm)
2.62M